Alzheimer's Drug Approved by Health Canada
Lecanemab aims to slow early stages of the disease by targeting plaques in the brain.
Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about its effectiveness and availability in Canada.
Lecanemab is a lab-made antibody given by intravenous infusion, targeting the buildup of amyloid plaque in the brain, a hallmark of Alzheimer's disease.
Lecanemab is not a cure and cannot reverse the disease or restore lost memories.
The Alzheimer Society of Canada calls it the first disease-modifying Alzheimer's treatment approved for use in the country.
Author's summary: Lecanemab approved to slow early Alzheimer's.
More News
- Thunder GM Sam Presti shares gut-wrenching Nikola Topic health news
- Russia Will Be Able to Send Cargo through Azerbaijan to Armenia - The Armenian Mirror-Spectator
- Somalia’s Entry into the East African Community: Gains and Setbacks – Puntland Post
- Dean Lewis Shares Statement Following Misconduct Allegations
- Distorted narratives risk reversing South Caucasus peace progress [OPINION]
- Jacob Elordi, Sydney Sweeney, & More to Receive 2026 SBIFF Virtuosos Award | News Channel 3-12
- Which Game Has the Best Graphics? | NorthPennNow
- Lawyers Petition UN Working Group on Arbitrary Detention to Order Immediate Release of Vicken Euljekjian - The Armenian Mirror-Spectator
- Stranger Things 5 trailer shows way more than we were ready for
- Billie Eilish Calls on Billionaires to Do More for People in Need